Key points
-
An abbreviated non-contrast magnetic resonance imaging (MRI) protocol to screen for hepatocellular carcinoma has been retrospectively investigated in 188 patients (28 of them with 42 malignancies)
-
This protocol demonstrated high specificity (93%) and negative predictive value (97%), with a sensitivity (85%) comparable to that of ultrasound and gadoxetic acid contrast-enhanced MRI
-
This screening method was robust to hepatic steatosis and may be considered an alternative to screen high-risk patients in the case of suboptimal ultrasound image quality
Background
Association/society, abbreviation, year [reference number] | Definition of high-risk population to be screened | Method of surveillance (interval when specified by the guideline) |
---|---|---|
European Association for the Study of the Liver, EASL, 2018 [9] | • Cirrhosis • F3 hepatic fibrosis • Non-cirrhotic hepatitis B patients with intermediate-high HCC risk (PAGE-B score or higher) | Ultrasound (6 months) |
Asian Pacific Association for the Study of the Liver, APASL, 2018 [8] | • Cirrhosis with hepatitis B or C infection, genetic haemochromatosis, primary biliary cirrhosis, alpha-1 antitrypsin deficiency, autoimmune hepatitis. • Non-cirrhotic chronic hepatitis B carrier in patients who are: o Asian female > 50 years o Asian male > 40 years o African > 20 years • Family history of HCC | Ultrasound (6 months) |
Combined American Association for the Study of Liver Disease, AASLD, 2018 [10] | Ultrasound + AFP (6 months) | |
Canadian Association for the Study of Liver Hepatocellular Carcinoma, CASL, 2015 [6] | Ultrasound ± AFP (6 months) | |
National Comprehensive Cancer Network, NCCN, 2018 [5] | Ultrasound ± AFP (6 months) | |
Korean Liver Cancer Study Group and the National Cancer Center, KLCSG-NCC, 2014 [13] | • Hepatitis B or C positive • Cirrhosis | Ultrasound + AFP (not stated) |
Japanese Society of Hepatology, JSH, 2015 [11] | Ultrasound + AFP and other serological markers (3–6 months depending on risk) | |
American College of Gastroenterology, ACG, 2014 [12] | • Suggestive of cirrhotic patients but not clearly stated | Ultrasound + AFP |
Methods
Subjects
MRI acquisition
Image analysis
Statistical analysis
Results
Sex | 95 females, 93 males |
Age* | 63 ± 13 (22–89) |
Cirrhosis | 44 (23.4%) |
Liver disease aetiology | |
HBV | 28 (14.9%) |
HCV | 13 (6.9%) |
NASH/NAFLD | 9 (4.8%) |
Alcohol | 7 (3.7%) |
Idiopathic cirrhosis | 5 (2.7%) |
Autoimmune hepatitis | 2 (1.0%) |
Other | 18 (9.6%) |
None | 106 (5.4%) |
Fatty liver | |
None | 152 (80.9%) |
Mild | 22 (11.7%) |
Moderate | 9 (4.7%) |
Severe | 5 (2.7%) |
Per-patient analysis
Sensitivity
Pooled | Reader 1 | Reader 2 | Reader 3 | |
---|---|---|---|---|
Overall | ||||
PPV | 71/106, 67.0% (57.1–75.6%) | 21/30, 70.0% (50.4–84.6%) | 23/32, 71.9% (53.0–85.6%) | 27/44, 61.4% (45.5–75.3%) |
NPV | 445/458, 97.2%, (95.1–98.4%) | 151/158, 95.6% (90.7–98.0%) | 151/156, 96.8% (92.3–98.8%) | 143/144, 99.3% (95.6–100.0%) |
Sensitivity | 71/84, 84.5%, (74.6–91.2%) | 21/28, 75.0% (54.8–88.6%) | 23/28, 82.1% (62.4–93.2%) | 27/28, 96.4% (79.7–99.8%) |
Specificity | 445/480, 92.7%, (89.9–94.8%) | 151/160, 94.4% (89.2–97.2%) | 151/160, 94.4% (89.3–97.2%) | 143/160, 89.4% (83.3–93.5%) |
Cirrhosis present | ||||
PPV | 51/61, 83.6% (71.5–91.4%) | 14/15, 93.3% (66.0–99.6%) | 17/20, 85.0% (61.1–96.0%) | 20/26, 76.9% (55.9–90.2%) |
NPV | 63/71, 88.7% (78.4–94.7%) | 23/29, 79.3% (59.7–91.2%) | 21/23, 91.3% (70.4–98.4%) | 19/19, 100% (79.1–100%) |
Sensitivity | 51/59, 86.4% (74.4–93.6%) | 14/20, 70.0% (45.7–87.1%) | 17/19, 89.4% (65.5–98.1%) | 20/20, 100% (79.9–100%) |
Specificity | 63/73, 86.3% (75.8–92.9%) | 23/24, 95.8% (76.9–99.8%) | 21/24, 87.5% (66.5–96.7%) | 19/25, 76% (54.5–89.8%) |
No cirrhosis | ||||
PPV | 21/47, 44.7% (30.5–59.8%) | 8/16, 50.0% (25.5–74.4%) | 6/12, 50.0% (22.3–77.7%) | 7/19, 36.8% (17.2–61.4%) |
NPV | 382/386, 99.0% (97.1–99.7%) | 128/129, 99.2% (95.1–100%) | 130/132, 98.5% (94.1–99.7%) | 124/125, 99.2% (95.0–100%) |
Sensitivity | 21/25, 84.0% (63.1–94.7%) | 8/9, 88.9% (50.7–99.4%) | 6/8, 75.0% (35.6–95.5%) | 7/8, 87.5% (46.7–99.3%) |
Specificity | 382/408, 93.6% (90.7–95.7%) | 128/136, 94.1% (88.3–97.2%) | 130/136, 95.6% (90.2–98.1%) | 124/136, 91.2% (84.8–95.2%) |
Steatosis present | ||||
PPV | 8/19, 42.1% (21.1–66.0%) | 3/7, 42.9% (11.8–79.8%) | 2/3, 66.7% (12.5–98.2%) | 3/9, 33.3% (9.0–69.1%) |
NPV | 88/89, 98.9% (93.0–99.9%) | 29/29, 100% (85.4–100%) | 32/33, 97.0% (82.5–99.9%) | 27/27, 100% (84.5–100%) |
Sensitivity | 8/9, 88.9% (50.7–99.4%) | 3/3, 100% (32.0–100%) | 2/3, 66.7% (12.5–98.2%) | 3/3, 100% (31.0–100%) |
Specificity | 22/99, 88.9% (80.6–94.1%) | 29/33, 87.9% (70.9–96.0%) | 32/33, 97.0% (82.5–99.9%) | 27/33, 81.8% (63.9–92.4%) |
No steatosis | ||||
PPV | 63/87, 72.4% (61.6–81.1%) | 18/23, 78.3% (55.8–91.7%) | 21/29, 72.4% (52.5–86.6%) | 24/35, 68.6% (50.6–82.6%) |
NPV | 357/369, 96.7% (94.2–98.2%) | 122/129, 94.6% (88.7–97.6%) | 119–123, 96.7% (91.4–99.0%) | 116/117, 99.1% (94.6–100%) |
Sensitivity | 63/75, 84.0% (73.3–91.1%) | 18/25, 72.0% (50.4–87.1%) | 21/25, 84.0% (63.1–94.7%) | 24/25, 96.0% (77.7–99.8%) |
Specificity | 357/381, 93.7% (90.6–95.8%) | 122/127, 96.0% (90.6–98.5%) | 119/127, 93.7% (87.6–97.0%) | 116/127, 91.3% (84.7–95.4%) |
Specificity
Negative predictive value
Positive predictive value
Per-lesion analysis
Per-lesion sensitivity | |
---|---|
Pooled overall | |
All malignant lesions (n = 42) | 97/126, 77.0% (68.5–83.8%) |
< 20 mm | 33/51, 64.7% (50.0–77.2%) |
≥ 20 mm | 64/75, 85.3% (74.8–92.1%) |
Reader 1 | |
All malignant lesions | 29/42, 69.0% (52.8–81.9%) |
< 20 mm | 10/17, 58.9% (33.5–80.6%) |
≥ 20 mm | 19/25, 76.0% (54.5–89.8%) |
Reader 2 | |
All malignant lesions | 28/42, 66.7% (50.4–80.0%) |
< 20 mm | 7/17, 41.2% (19.4–66.5%) |
≥ 20 mm | 21/25, 84.0% (63.1–94.7%) |
Reader 3 | |
All malignant lesions | 40/42, 95.2% (82.6–99.2%) |
< 20 mm | 16/17, 94.1% (68.2–99.7%) |
≥ 20 mm | 24/25, 96.0% (77.7–99.8%) |
Interobserver variability
Readers (κ value) | |||
---|---|---|---|
R1, R2 | R1, R3 | R2, R3 | |
All patients (n = 188) | 0.54 | 0.57 | 0.51 |
Fatty liver | |||
Yes (n = 36) | 0.32 | 0.68 | 0.24 |
No (n = 152) | 0.58 | 0.54 | 0.57 |
Cirrhosis | |||
Yes (n = 44) | 0.49 | 0.48 | 0.60 |
No (n = 144) | 0.47 | 0.53 | 0.25 |
LI-RADS 4, 5 and M lesions (n = 51) | 0.23 | 0.32 | 0.25 |
< 20 mm | -0.04 | 0.30 | 0.12 |
≥ 20 mm | 0.26 | 0.23 | 0.36 |